Biocon appoints S.R. Batliboi as statutory auditor for five years
Biocon Limited reported 13% revenue growth and approved a ₹0.50 dividend at its 48th AGM. Key governance changes include the appointment of S.R. Batliboi & Associates LLP as statutory auditors for five years and the reappointment of Eric Vivek Mazumdar as director.
*this image is generated using AI for illustrative purposes only.
Biocon Limited shareholders approved a final dividend of ₹0.50 per equity share and adopted a comprehensive new long-term incentive plan at the company’s 48th Annual General Meeting (AGM) held on August 06, 2026. The meeting also saw the appointment of S.R. Batliboi & Associates LLP as statutory auditors for a five-year term and the reappointment of Eric Vivek Mazumdar as a director. These resolutions signal continued capital discipline and alignment of management interests with shareholder value amidst the company’s strategic consolidation of its biosimilars and generics businesses.
The Board placed nine resolutions before the members, eight of which were passed via e-voting. In addition to the dividend declaration, shareholders approved the formulation of the Biocon Unity Long Term Incentive Plan 2026, which includes performance stock units, restricted stock units, and an employee stock purchase plan. The resolution authorized financial assistance to the Biocon India Limited Employees Welfare Trust to acquire shares for implementing these equity-based incentives. The tenure of outgoing independent directors Bobby Kanubhai Parikh and Nicholas Robert Haggard concluded with the meeting, alongside the completion of the term for statutory auditors B S R & Co. LLP.
Financial Performance and Strategic Consolidation
Executive Chairperson Kiran Mazumdar-Shaw reported that operating revenues grew by 13% in FY26, while EBITDA margins expanded by nearly 200 basis points. The biosimilars segment drove this growth, delivering 16% revenue growth and a 40% increase in EBITDA on a comparable basis. A key strategic milestone was the consolidation of Biocon Biologics as a wholly owned subsidiary, integrating biosimilars, insulins, complex generics, and GLP-1 peptides under a single organizational structure.
To fund this transition and strengthen its balance sheet, Biocon raised nearly US$1 billion through two Qualified Institutions Placements (QIPs). The proceeds were utilized to consolidate full ownership of the biosimilars business, retire structured debt, and improve the company’s credit profile. Mazumdar-Shaw noted that these investments position Biocon as one of the global top five biosimilars companies by revenue and the third-largest supplier of insulins by volume.
Key Resolutions Passed
The following table summarizes the key outcomes of the 48th AGM:
| Resolution Type | Key Detail | Outcome |
|---|---|---|
| Ordinary | Final Dividend Declaration | Approved: ₹0.50 per equity share for FY26 |
| Ordinary | Statutory Auditor Appointment | Approved: S.R. Batliboi & Associates LLP (5-year term) |
| Ordinary | Director Reappointment | Approved: Eric Vivek Mazumdar (DIN: 09381549) |
| Special | Equity Incentive Plan | Approved: Biocon Unity Long Term Incentive Plan 2026 |
| Special | Financial Assistance | Approved: Funding for Employee Welfare Trust share acquisition |
| Ordinary | Cost Auditor Remuneration | Ratified remuneration for FY27 |
Governance Updates
S.R. Batliboi & Associates LLP, Chartered Accountants (Firm Registration No. 101049W/E300004), was appointed as Statutory Auditors for a term of five consecutive years, holding office from the conclusion of the 48th AGM until the conclusion of the 53rd AGM in 2031. This appointment follows the expiration of the term of B S R & Co. LLP (Firm Registration No. 101248W/W100022). Eric Vivek Mazumdar, son of Prof. Ravi Mazumdar and nephew of Kiran Mazumdar-Shaw, was reappointed as a director liable to retire by rotation. The company confirmed that Mazumdar is not debarred from holding office by any order of SEBI or other authorities.
What the Numbers Show
The simultaneous approval of a cash dividend and a substantial equity-based incentive plan reflects a dual focus on immediate shareholder returns and long-term retention of talent critical to the company’s scientific leadership. With R&D investment maintained at 7–9% of revenues, the shift toward GLP-1 peptides and diabetes-obesity treatments suggests that future growth will be driven by high-margin specialty biologics rather than volume alone. The successful execution of a US$1 billion QIP without diluting existing shareholders significantly indicates strong institutional confidence in the post-consolidation strategy led by CEO Shreehas Tambe.
Historical Stock Returns for Biocon
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.68% | +1.28% | +2.90% | +18.71% | +17.26% | +13.65% |
How will the integration of GLP-1 peptides into Biocon's portfolio impact its competitive positioning against global pharma giants in the diabetes and obesity treatment market?
What specific performance metrics are tied to the new Biocon Unity Long Term Incentive Plan, and how might they influence management's strategic priorities over the next five years?
Given the recent US$1 billion QIP, what is Biocon's projected timeline for achieving net debt reduction, and how will this affect future capital allocation decisions?
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
